Shares in Xvivo Perfusion AB will begin trading on NASDAQ OMX First North on October 8, 2012

Xvivo Perfusion AB was spun off from Vitrolife AB on October 1, whereby Vitrolife shareholders received one share in Xvivo Perfusion for each share in Vitrolife. Xvivo Perfusion shares have been approved for trade on NASDAQ OMX First North and the first day for trade will be October 8.

In view of the listing on First North, Xvivo Perfusion is today publishing a company description that is available on the company’s website.

October 4, 2012
Gothenburg
Xvivo Perfusion AB (publ)
Magnus Nilsson
CEO

For further information, please contact:
Magnus Nilsson, CEO or Christoffer Rosenblad, CFO Xvivo Perfusion AB
Tel: +46 31 788 21 50 (switchboard) or +46 31 788 21 59 (Christoffer direct)

The information was submitted for publication on October 4, 2012 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Xvivo Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North as of October 8, 2012 and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye www.redeye.se.
_______________________________________________________________________________________________________________________________________

Xvivo Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Tags: